Wave Life Sciences, Inc. Stock 12‑Month Price Target Cut to $18.02, Implies 461% Upside

What happened

The average 12-month price target for Wave Life Sciences stock from 20 analysts fell from $18.42 to $18.02, with forecasts ranging from $8.37 to $42 per share. Based on the Oct. 26 closing price, the new target implies about 461% potential upside.

Confirmed

Global impact / market context

A lower average target means analysts on balance expect slightly less upside than before, even though the consensus rating stays at Buy with 20 Buys, 1 Hold and 0 Sells. The wide $8.37 to $42 range shows strong disagreement about the company's future value.

Analyst inference

The small cut from $18.42 to $18.02 suggests only modest changes to analyst expectations, not a broad loss of confidence. Because the target is far above the Oct. 26 closing price, investors see a large gap between analyst views and the current share price.

Analyst inference

What to watch

1. Watch whether more of the 21 covering analysts shift their rating away from Buy, since the consensus currently holds 20 Buys, 1 Hold and 0 Sells. Confirmed
2. Watch whether analysts move their individual targets toward the low $8.37 or high $42 ends of the range, which would signal growing agreement or disagreement on value. Proposed
3. Watch the next average target update: another cut would suggest fading confidence in future revenue or profits, while a rise would suggest improving expectations. Analyst inference

Evidence

• Original source link unavailable